| Literature DB >> 29650474 |
J Dhanda1, L Rennie2, R Shaw3.
Abstract
Recent guidelines from the National Institute for Health and Care Excellence (NICE) have suggested that the medical management of osteoradionecrosis (ORN) of the jaws should be used in clinical trials only, and some drugs and therapeutics committees have withdrawn funds for such prescriptions. With increased scrutiny on the use of these agents, the aims of this study were to ascertain current trends in the presentation and management of ORN, with particular focus on which agents are being used.Entities:
Keywords: Medical management; Osteoradionecrosis; Trends; Triple therapy
Mesh：
Substances：
Year: 2018 PMID： 29650474 DOI： 10.1016/j.bjoms.2018.03.009
Source DB: PubMed Journal: Br J Oral Maxillofac Surg ISSN： 0266-4356 Impact factor: 1.651